West Pharmaceutical Services Inc (BSP:W2ST34)

R$ 51.9 0 (0%) Market Cap: 131.56 Bil Enterprise Value: 130.48 Bil PE Ratio: 46.70 PB Ratio: 8.29 GF Score: 92/100

Q2 2024 West Pharmaceutical Services Inc Earnings Call Transcript

Jul 25, 2024 / 01:00 PM GMT

Release Date Price: R$50.35

Transcript 10-Q8-K

Key Points

Positve

West Pharmaceutical Services Inc (WST) expects the second half of the year to be stronger than the first half, with a return to year-over-year organic growth in the fourth quarter.
The company has a strong position in biologics, which is the fastest-growing segment within injectables.
Ongoing capital expansion projects are expected to drive increased capacity and address new opportunities.
The company has received accolades for its sustainability efforts, including being named one of America's Most Responsible Companies by Newsweek.
West Pharmaceutical Services Inc (WST) is seeing promising signs from customers that indicate a turning point in the destocking trend.

Negative

The company experienced a mid-single digit decline in organic sales and declines in operating profit and diluted EPS compared to the second quarter of 2023.
Customer destocking continued at a higher rate than anticipated, impacting sales negatively.
The company had to lower its full-year 2024 guidance due to a more gradual recovery than previously expected.
Adjusted operating profit margin decreased by 650 basis points from the same period last year.
The company recorded a significant decline in adjusted diluted EPS, down 28% for Q2.

Refinitiv StreetEvents Event Transcript
E D I T E D V E R S I O N

WST.N - West Pharmaceutical Services Inc
Q2 2024 West Pharmaceutical Services Inc Earnings Call
Jul 25, 2024 / 01:00PM GMT

=====================
Presentation
--------------------------------------------------------------------------------
Operator [1]
--------------------------------------------------------------------------------
Yes, good morning, and welcome to West's second quarter 2024 conference call.

--------------------------------------------------------------------------------
Unidentified_2 [2]
--------------------------------------------------------------------------------
By way of introduction, this is John Sweeney, the new Head of Investor Relations at West. I'm delighted to be here and I look forward to working with all of you. We issued our financial results earlier this morning, and the release has been posted to the Investors section on the Company's website located at westpharma.com.

On the call today, we will review our financial results, provide an update on our business and present an

Already have an account? Log in

Get the full story

Start 7-Day Free Trial

	Access to All Earning Calls and Stock Analysis
	30-Year Financial on one screen
	All-in-one Stock Screener with unlimited filters
	Customizable Stock Dashboard
	Real Time Insider Trading Transactions
	8,000+ Institutional investors’ 13F holdings
	Powerful Excel Add-in and Google sheets Add-on
	All data downloadable
	Quick customer support
	And much more...

30-Day 100% money back guarantee

You are not charged until the trial ends. Subscription fee may be tax deductible.

Excellent

4.6 out of 5

Trustpilot

Research Tools

All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Discussion Board

Product

Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Instant Alerts Mobile App 中文

Education

Financial Glossary Tutorials FAQ Schedule Free Session Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Fed Net Liquidity Buffett Assets Allocation

Company

About GuruFocus Career Contact Us Advertise Site Map Term of Use Privacy Policy Referral Program Partner Program

Survey

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!

Take Survey

Disclaimers

GuruFocus.com is not operated by a broker or a dealer. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes are provided by QuoteMedia, Inc. (CSI). Company fundamental data is provided by Morningstar. Analyst estimates data is sourced from both Refinitiv and Morningstar, with priority given to Refinitiv data. Data is updated daily.